Clinical Development of Crispr-Cas3 Phage Cocktail for the Treatment of Recurrent Urinary Tract Infections Caused by Escherichia Coli Including Antimicrobial and Multi-Drug Resistant Strains
Contract Overview
Contract Amount: $73,885,104 ($73.9M)
Contractor: Locus Biosciences Inc
Awarding Agency: Department of Health and Human Services
Start Date: 2020-09-28
End Date: 2026-12-31
Contract Duration: 2,285 days
Daily Burn Rate: $32.3K/day
Official Description: CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS
Place of Performance
Location: North Carolina, 27560